- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07669558
Electrical Impedance Tomography-Guided Identification of the Optimal Lateral Position in Postoperative ARDS
Effect of Left Lateral, Right Lateral, and Supine Positioning on Ventilation-Perfusion Matching Assessed by Electrical Impedance Tomography in Adult Postoperative Abdominal Surgery Patients With ARDS: A Prospective Randomized Crossover Physiological Study
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
Postoperative abdominal surgery patients commonly develop atelectasis, diaphragmatic dysfunction, and heterogeneous ventilation. When complicated by ARDS, ventilation-perfusion mismatch may worsen oxygenation and ventilatory efficiency. Prone positioning may be limited in this population because of abdominal incisions, drains, and intra-abdominal pressure concerns. Lateral positioning is frequently used in critical care and may improve V/Q coupling by changing gravitational gradients, chest wall mechanics, and pulmonary blood flow distribution; however, quantitative bedside evidence comparing left and right lateral positions is limited.
EIT is a radiation-free bedside functional imaging technique that can continuously monitor regional ventilation. In combination with a brief breath-hold and an intravenous tracer bolus, EIT can derive perfusion-related signals, enabling bedside quantification of V/Q matching.
In this randomized crossover study, each participant undergoes three body positions-supine position, left lateral position, and right lateral position-in a randomized order. The sequence (including whether left lateral or right lateral is performed first) is determined by random-number-based randomization. Each position stage lasts 60 minutes. After entering each position, participants are stabilized for 45 minutes before EIT measurements. EIT ventilation recording is obtained after stabilization, followed by an EIT perfusion assessment performed during a breath-hold of at least 8 seconds (actual breath-hold time recorded). During the breath-hold, a rapid intravenous tracer bolus is administered: 10 mL of 10% sodium chloride solution or 10 mL of 5% sodium bicarbonate solution, injected over 2-3 seconds via a central or peripheral venous line. Between position stages, participants return to the supine position for a 45-minute washout period. The primary endpoint is the difference in global normal V/Q (%) among the three positions. Secondary endpoints include other EIT-derived V/Q indices, oxygenation indices, respiratory mechanics, hemodynamic changes, and feasibility/safety outcomes.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Rui Zhang
- Telefonnummer: +86 18801119381
- E-mail: ccmzhangrui@foxmail.com
Studiesteder
-
-
-
Shanghai, Kina
- Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Department of Critical Care Medicine
-
Kontakt:
- Rui Zhang
- Telefonnummer: +86 18801119381
- E-mail: ccmzhangrui@foxmail.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Age ≥18 years
- Postoperative abdominal surgery patients admitted to the ICU with ARDS (Berlin definition)
- Considered able to tolerate protocolized position changes by the treating team
- EIT belt placement and protocol procedures feasible
- Informed consent obtained from the patient or legally authorized representative
Exclusion Criteria:
- Contraindication to lateral positioning (e.g., unstable spine, uncontrolled bleeding, open abdomen, high-risk surgical wound condition)
- Severe hemodynamic instability or other conditions making participation unsafe
- High risk of airway/vascular line/drain dislodgement not manageable
- Pregnancy
- Refusal of informed consent
- Any other condition deemed inappropriate by investigators
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Arm 1: Supine Position
Supine position with protocolized stabilization and EIT ventilation/perfusion measurements.
|
Using a randomized crossover design, all subjects undergo three body position stages in random order. Each position (supine, left lateral, right lateral) is maintained for 60 minutes. Vital signs are stabilized per protocol, followed by EIT assessment of ventilation-perfusion matching.
|
|
Eksperimentel: Arm 2: Left Lateral Position
Left lateral position with protocolized stabilization and EIT ventilation/perfusion measurements.
|
Using a randomized crossover design, all subjects undergo three body position stages in random order. Each position (supine, left lateral, right lateral) is maintained for 60 minutes. Vital signs are stabilized per protocol, followed by EIT assessment of ventilation-perfusion matching.
|
|
Eksperimentel: Right Lateral Position
Right lateral position with protocolized stabilization and EIT ventilation/perfusion measurements.
|
Using a randomized crossover design, all subjects undergo three body position stages in random order. Each position (supine, left lateral, right lateral) is maintained for 60 minutes. Vital signs are stabilized per protocol, followed by EIT assessment of ventilation-perfusion matching.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Global normal V/Q (%) derived from electrical impedance tomography (EIT)
Tidsramme: Post-stabilization in each body position (supine, left lateral, right lateral); assessments performed once per 60-minute positional stage, with comparative data reported for each position time point.
|
The percentage of lung pixels categorized as "normal ventilation-perfusion (V/Q)" according to pre-defined ventilation and perfusion signals acquired via EIT.
|
Post-stabilization in each body position (supine, left lateral, right lateral); assessments performed once per 60-minute positional stage, with comparative data reported for each position time point.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
EIT-derived V/Q mismatch components (shunt-like lung pixel percentage, dead-space-like lung pixel percentage).
Tidsramme: Single assessment time point after respiratory and hemodynamic stabilization within each 60-minute positional stage (left lateral, right lateral); all V/Q mismatch data will be reported separately per positional time point for inter-position comparison.
|
Quantitative ventilation-perfusion mismatch metrics calculated from electrical impedance tomography (EIT) ventilation and perfusion signals, unit: %. Shunt-like %: Proportion of lung pixels with high perfusion but negligible ventilation Dead-space-like %: Proportion of lung pixels with robust ventilation but minimal perfusion These two indicators quantify the severity of pulmonary gas exchange disturbance under different body positions. |
Single assessment time point after respiratory and hemodynamic stabilization within each 60-minute positional stage (left lateral, right lateral); all V/Q mismatch data will be reported separately per positional time point for inter-position comparison.
|
|
EIT-derived regional ventilation distribution indices
Tidsramme: Single assessment time point after hemodynamic and respiratory stabilization within each 60-minute positional stage (left lateral, right lateral); comparative data of all indices will be reported separately for each positional assessment time point.
|
A composite set of regional ventilation distribution parameters calculated from EIT signals, including center of ventilation (CoVX, CoVY), dorsal ventilation ratio (DVR), global inhomogeneity index (GI), ventral/dorsal impedance ratio, and ventilation fraction of four predefined ventrodorsal lung regions (ventral, mid-ventral, mid-dorsal, dorsal, expressed as %), used to evaluate regional ventilation uniformity and spatial distribution.
|
Single assessment time point after hemodynamic and respiratory stabilization within each 60-minute positional stage (left lateral, right lateral); comparative data of all indices will be reported separately for each positional assessment time point.
|
|
EIT-derived regional perfusion distribution indices
Tidsramme: Single perfusion assessment time point after respiratory and hemodynamic stabilization within each 60-minute positional stage (left lateral, right lateral); all perfusion index data will be reported separately for each positional assessment time point.
|
Quantitative perfusion parameters calculated from electrical impedance tomography (EIT) perfusion signals, including perfusion center coordinates (CoPX, CoPY), dorsal perfusion ratio (DPR), global perfusion inhomogeneity index, regional perfusion delay, and perfusion percentage of four predefined ventrodorsal lung regions (ventral, mid-ventral, mid-dorsal, dorsal, unit: %).
These indices quantitatively characterize spatial perfusion redistribution, perfusion homogeneity, and temporal perfusion lag in supine, left lateral and right lateral positions.
|
Single perfusion assessment time point after respiratory and hemodynamic stabilization within each 60-minute positional stage (left lateral, right lateral); all perfusion index data will be reported separately for each positional assessment time point.
|
|
Oxygenation index (PaO₂/FiO₂ ratio if arterial blood gas sampling is feasible; SpO₂/FiO₂ ratio as an alternative surrogate index).
Tidsramme: Single assessment time point after respiratory and hemodynamic stabilization within each 60-minute positional stage (supine, left lateral, right lateral); oxygenation index values will be reported separately for each positional assessment time point.
|
Oxygenation index is calculated to reflect systemic oxygenation status.
PaO₂/FiO₂ ratio (unit: mmHg) will be prioritized when arterial blood gas data are available; if arterial blood gas cannot be obtained, SpO₂/FiO₂ ratio will be adopted as the substitute parameter.
|
Single assessment time point after respiratory and hemodynamic stabilization within each 60-minute positional stage (supine, left lateral, right lateral); oxygenation index values will be reported separately for each positional assessment time point.
|
|
Ventilator-related pressure parameters (plateau pressure, driving pressure).
Tidsramme: Single assessment time point after respiratory and hemodynamic stabilization within each 60-minute positional stage (supine, left lateral, right lateral); all pressure values will be reported separately for each positional assessment time point.
|
Static respiratory pressure indicators automatically recorded by mechanical ventilator, only collected from participants receiving invasive mechanical ventilation.
|
Single assessment time point after respiratory and hemodynamic stabilization within each 60-minute positional stage (supine, left lateral, right lateral); all pressure values will be reported separately for each positional assessment time point.
|
|
Respiratory system compliance (ventilator-derived parameter).
Tidsramme: Single assessment time point after respiratory and hemodynamic stabilization within each 60-minute positional stage (supine, left lateral, right lateral; all compliance values will be reported separately for each positional assessment time point.
|
A comprehensive respiratory mechanics index calculated as tidal volume divided by driving pressure, unit: mL/cmH₂O.
Measurement is limited to invasively ventilated participants to evaluate the overall distensibility of lungs and chest wall.
|
Single assessment time point after respiratory and hemodynamic stabilization within each 60-minute positional stage (supine, left lateral, right lateral; all compliance values will be reported separately for each positional assessment time point.
|
|
Circulatory monitoring parameters (heart rate, mean arterial pressure, vasopressor use if available).
Tidsramme: Two predefined assessment time points within each 60-minute positional stage (supine, left lateral, right lateral): 1) after full respiratory and hemodynamic stabilization; 2) around breath-hold and contrast bolus injection for perfusion acquisition.
|
Continuous hemodynamic readings collected via bedside invasive monitor for circulatory assessment.
|
Two predefined assessment time points within each 60-minute positional stage (supine, left lateral, right lateral): 1) after full respiratory and hemodynamic stabilization; 2) around breath-hold and contrast bolus injection for perfusion acquisition.
|
|
Proportion of participants completing all randomized 60-minute positional stages and inter-position washout periods.
Tidsramme: Through study positional phase completion (from initiation of the first positional stage to the end of the final washout period following the last positional assessment); completion status data will be summarized across all participants.
|
Binary participant-level endpoint (unit: proportion [%]) calculated as the number of participants who fully finished all three predefined body position stages and corresponding washout intervals divided by total enrolled participants.
Used to assess overall study procedural feasibility.
|
Through study positional phase completion (from initiation of the first positional stage to the end of the final washout period following the last positional assessment); completion status data will be summarized across all participants.
|
|
Number of participants with successful acquisition of analyzable EIT imaging datasets.
Tidsramme: Through study positional phase completion (from initiation of the first positional stage to the end of the final washout period following the last positional assessment); successful EIT acquisition counts will be aggregated for all enrolled subjects.
|
Count-based feasibility metric (unit: number of participants).
Defined as participants with complete, artifact-free EIT ventilation and perfusion images eligible for post-hoc quantitative regional lung function analysis.
|
Through study positional phase completion (from initiation of the first positional stage to the end of the final washout period following the last positional assessment); successful EIT acquisition counts will be aggregated for all enrolled subjects.
|
|
Proportion of participants capable of maintaining breath-hold for at least 8 seconds during EIT perfusion imaging.
Tidsramme: Through positional phase completion (from first positional stage start to final post-position washout end); breath-hold compliance proportions summarized across all perfusion assessment time points.
|
Proportional feasibility endpoint (unit: proportion [%]).
Calculated as participants who sustained ≥8-second breath-hold during contrast bolus perfusion scans divided by all participants undergoing EIT perfusion measurement.
|
Through positional phase completion (from first positional stage start to final post-position washout end); breath-hold compliance proportions summarized across all perfusion assessment time points.
|
|
Number of participants with any procedure-related adverse event (desaturation, hypotension, arrhythmia, accidental tube/line/drain displacement).
Tidsramme: Through positional phase completion (from first positional stage start to final post-position washout end); all adverse events captured and tallied during positional testing.
|
Safety count endpoint (unit: number of participants).
Captures all acute adverse events directly associated with positional changes and EIT image acquisition during the study protocol.
|
Through positional phase completion (from first positional stage start to final post-position washout end); all adverse events captured and tallied during positional testing.
|
|
Number of participants with early study termination secondary to positional intolerance.
Tidsramme: Through positional phase completion (from first positional stage start to final post-position washout end); all early termination events documented and counted for pooled safety analysis.
|
Tolerability safety metric (unit: number of participants).
Records participants withdrawn prematurely from positional testing due to respiratory, hemodynamic or clinical intolerance to supine, left lateral or right lateral positioning.
|
Through positional phase completion (from first positional stage start to final post-position washout end); all early termination events documented and counted for pooled safety analysis.
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ARDS-EIT-POS-001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Akut Respiratory Distress Syndrome (ARDS)
-
Rise Therapeutics LLCIkke rekrutterer endnuAcute respiratory distress syndrom
-
PT. Prodia Stem Cell IndonesiaRumah Sakit Pusat Angkatan Darat Gatot SoebrotoRekrutteringAcute respiratory distress syndromIndonesien
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Ikke rekrutterer endnu
-
Changchun Tuohua Pharmaceutical Co., Ltd.RekrutteringAcute respiratory distress syndromKina
-
Southeast University, ChinaRekrutteringAcute respiratory distress syndromKina
-
Southeast University, ChinaRekrutteringAcute respiratory distress syndromKina
-
Assiut UniversityIkke rekrutterer endnuAcute respiratory distress syndrom
-
Breathe Biologics, Inc.Ikke rekrutterer endnu
-
Wu RongzhouAfsluttetAcute respiratory distress syndrom | Lungebetændelse hos børn | Åndedrætssvigt (pædiatriske patienter)Kina
-
Centre Hospitalier Universitaire, AmiensIkke rekrutterer endnuAcute respiratory distress syndrom | Ventilator-induceret lungeskade | Højde | Tidevandsvolumen | Forventet kropsvægtFrankrig
Kliniske forsøg med Positioning Intervention
-
Anderson Orthopaedic Research InstituteAfsluttetTotal hofteudskiftning
-
Vanderbilt University Medical CenterNational Institute on Deafness and Other Communication Disorders (NIDCD)Trukket tilbageAkustisk neuromForenede Stater
-
Navotek Medical, Ltd.AfsluttetProstatakræftBelgien, Holland
-
Kirsehir Ahi Evran UniversityAfsluttet
-
Biolux Research Holdings, Inc.AfsluttetOrtodontisk tandbevægelseCanada
-
University of FloridaAfsluttetFølsomhedForenede Stater
-
Roswell Park Cancer InstituteAfsluttetFedme | Overvægtig | Anatomisk fase I brystkræft AJCC v8 | Anatomisk fase IA brystkræft AJCC v8 | Anatomisk fase IB brystkræft AJCC v8 | Anatomisk fase II brystkræft AJCC v8 | Anatomisk fase IIA brystkræft AJCC v8 | Anatomisk fase IIB brystkræft AJCC v8 | Anatomisk fase III brystkræft AJCC v8 | Anatomisk fase... og andre forholdForenede Stater
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RekrutteringBiokemisk tilbagevendende prostatakarcinom | Fase IV prostatakræft AJCC v8 | Stage IVA prostatakræft AJCC v8 | Stadie IVB prostatakræft AJCC v8 | Metastatisk prostataadenokarcinomForenede Stater
-
University of WashingtonNational Cancer Institute (NCI)AfsluttetAvanceret malignt neoplasmaForenede Stater
-
Universidad de ExtremaduraDiputación Provincial de BadajozRekrutteringSundhedsuddannelse | Gamification in Health EducationSpanien